Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial. - Hall N; Allavena C; Katlama C; Jobert A; Molina JM; Cua E; Bani-Sadr F; Hocqueloux L; Duvivier C; Merrien D; Hikombo H; André-Garnier E; et al. (AIDS research and therapy, 2022)